Reformulated imatinib eliminates morphine tolerance in lab studies

By reformulating the common cancer drug imatinib (Gleevec), researchers have eliminated morphine tolerance in rats – an important step toward improving the effectiveness of chronic pain management in patients, according to researchers at The University of Texas MD Anderson Cancer Center.

Narcotics such as morphine are a mainstay of chronic pain treatment. Over time, to the pain-relieving effects of these drugs can develop, requiring increasing doses to control pain. In some cases, narcotics become ineffective. This study, published online in Nature Medicine, is the first to identify a cellular signal that selectively causes narcotic tolerance.

"By suggesting a way to prevent or reverse tolerance in patients, this study could have far-reaching implications for many people suffering with chronic intractable pain," said senior author Howard B. Gutstein, M.D., professor in the Departments of Anesthesiology/Perioperative Medicine and Biochemistry at MD Anderson.

One imatinib target causes morphine tolerance

In the study, scientists discovered that activating the β - isoform of the platelet-derived growth factor receptor (PDGFR) caused morphine tolerance in animals not previously exposed to morphine.

Imatinib is commonly used to treat certain types of leukemia and gastrointestinal tumors. It targets a number of cellular receptors, including the PDGFR, which is heavily expressed in those cancer cells.

In this study, imatinib prevented morphine tolerance, and importantly, completely reversed tolerance in that received high morphine doses continuously for several days, which reflects how morphine and other opioids are often given to patients.

Researchers modify imatinib to block PDGFR

Morphine and other opioids work by binding to mu opioid receptorsin the brain and spinal cord.

Imatinib's ability to inhibit morphine tolerance has not yet been observed in cancer patients who take imatinib because the drug does not penetrate the nervous system. Gutstein's group reformulated imatinib using a simple, clinically approved carrier molecule called Captisol that markedly increased drug delivery to the brain.

"What's particularly exciting is that imatinib already is approved for use in humans, which suggests that we might be able to utilize this discovery to treat patients fairly soon," Gutstein said. He emphasized that the reformulated must first be tested for efficacy and safety in further animal studies, then in humans in a Phase I study.

Potential to reduce debilitating side effects

"Many patients in severe pain often refuse high doses of opioids because of the side effects, and they desperately need relief," Gutstein said. "We may be able to quickly translate this discovery and dramatically reduce the suffering endured by the sickest patients, and not just those with cancer."

Patients taking morphine and other opioids can experience side effects ranging from unpleasant to life-threatening in their intensity, including itching, constipation, nausea and breathing depression. Reducing tolerance could allow the use of lower doses to relieve pain with fewer .

Related Stories

Researchers find new target to improve pain management

Sep 07, 2010

Researchers from Mount Sinai School of Medicine have discovered a major mechanism underlying the development of tolerance to chronic morphine treatment. The discovery may help researchers find new therapies to treat chronic ...

New medication more potent, longer lasting than morphine

Jan 04, 2011

(PhysOrg.com) -- A little-known morphinelike drug is potentially more potent, longer lasting and less likely to cause constipation than standard morphine, a study led by a Loyola University Health System anesthesiologist ...

Morphine dependency blocked by single genetic change

Jan 28, 2008

Morphine’s serious side effect as a pain killer – its potential to create dependency – has been almost completely eliminated in research with mice by genetically modifying a single trait on the surface of neurons. The ...

Recommended for you

Flu vaccine for expectant moms a top priority

49 minutes ago

Only about half of all pregnant women in the U.S. get a flu shot each season, leaving thousands of moms-to-be and their babies at increased risk of serious illness.

Experts want restrictions on testosterone drug use (Update)

22 hours ago

Federal health experts said Wednesday there is little evidence that testosterone-boosting drugs are effective for treating common signs of aging in men and that their use should be narrowed to exclude millions of Americans ...

Big cities take aim at prescription painkillers

Sep 16, 2014

Some of the nation's largest cities are ratcheting up their criticism of prescription painkillers, blaming the industry for a wave of addiction and overdoses that have ravaged their communities and busted local budgets.

World Health Organization policy improves use of medicines

Sep 16, 2014

In this issue of PLOS Medicine, Kathleen Holloway from WHO and David Henry (University of Toronto, Canada) evaluated data on reported adherence to WHO essential medicines practices and measures of quality use of medicines from 5 ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

tadchem
not rated yet Feb 21, 2012
This also has potential to revolutionize the treatment of opiate addiction.
ziphead
not rated yet Feb 21, 2012
"Reformulated imatinib eliminates morphine tolerance in lab studies"

And so does agmatine. Too bad it cannot be patented by Novartis.
NeptuneAD
not rated yet Feb 21, 2012
Sooner the better, I really dislike having to put up with pain just so I don't become tolerant to the point where I can't put up with the pain.